8-K
filed February 2, 2023, 6:59 PM ET
ticker PBH
CIK 0001295947
earnings
confidence high
sentiment positive
materiality 0.65
Prestige Q3 revenue $275.5M (+0.4%), EPS $1.04 (+5.1%); guides FY23 EPS ~$4.18
Prestige Consumer Healthcare Inc.
2023-Q3 EPS reported
$3.14
revenue$841,856,000
- Q3 revenue $275.5M (+0.4% YoY; +1.8% ex-currency); diluted EPS $1.04 (+5.1% vs $0.99).
- International OTC revenue $38.6M (+15% YoY); North American OTC $236.9M (-1.7%).
- Leverage ratio reduced to 3.5x, lowest in over 10 years; net debt ~$1.4B.
- FY2023 guidance: revenue $1,120-1,122M, diluted EPS ~$4.18, free cash flow ~$220M.
- Nine-month revenue $841.9M (+2.7% YoY); net income $158.2M vs $153.3M.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Prestige Consumer Healthcare Inc. reported third fiscal quarter ended December 31, 2022 results: revenue $275.5 million, net income $52.0 million, EPS $1.04.
- Period
- third fiscal quarter ended December 31, 2022
- Revenue
- $275.5 million
- Net income
- $52.0 million
- EPS
- $1.04
- Result
- reported results
Exact text from the filing
Reported revenues in the third quarter of fiscal 2023 of $275.5 million increased 0.4% from $274.5 million in the third quarter of fiscal 2022. Revenues increased 1.8% excluding the impact of foreign currency. The revenue growth for the quarter was led by strong performance in our International OTC segment and strong Cough & Cold category sales versus the prior year comparable period. Reported net income for the third quarter of fiscal 2023 totaled $52.0 million, compared to the prior year third quarter’s net income of $50.2 million. Diluted earnings per share of $1.04 for the third quarter of fiscal 2023 compared to diluted earnings per share of $0.99 in the prior year comparable period.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Prestige Consumer Healthcare Inc. reported fiscal year 2023 results: revenue $1,120 and $1,122.
- Period
- fiscal year 2023
- Revenue
- $1,120 and $1,122
- Result
- guidance update
Exact text from the filing
With one quarter to go in fiscal year 2023 we anticipate sales between $1,120 and $1,122 equating to over 3% growth on top of our record fiscal 2022 results.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.